Healthy volunteers help calibrate new CML drug
NCT ID NCT05623774
First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tested a new drug called IkT-001Pro in 64 healthy adults aged 18 to 55. The goal was to see how the body processes it compared to the standard cancer drug imatinib, and to check for side effects. Participants took single doses of each drug with a week in between. This is an early-stage study with no direct treatment benefit for volunteers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.